Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Substance Use Disorders Affecting Sleep01:24

Substance Use Disorders Affecting Sleep

196
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
196
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

338
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
338
Pharmacovigilance01:19

Pharmacovigilance

890
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
890
Drug Therapy01:28

Drug Therapy

69
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
69
Drug Dependence01:17

Drug Dependence

1.1K
Medications are typically administered to achieve therapeutic effects. Some drugs can modify an individual's mood and perception, frequently resulting in various enjoyable experiences. However, this can result in drug dependency, a condition marked by continuous drug use despite potential negative consequences. Drug dependency primarily falls into two categories: psychological and physical dependence. Psychological dependence occurs when the pleasurable feelings induced by the drug...
1.1K
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

515
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
515

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ebola Virus in Pregnancy.

Obstetrics and gynecology·2026
Same author

Experiences of pregnant and postpartum people of color engaged in a randomized clinical trial of medication to treat opioid use disorder during pregnancy: A "Positive Outliers" analysis.

Journal of substance use and addiction treatment·2026
Same author

Strengthening Prevention and Treatment of HIV, Viral Hepatitis, Sexually Transmitted Infections, and Tuberculosis Among Women Who Are Justice System-Involved: CDC Recommendations and Resources.

Journal of women's health (2002)·2026
Same author

Extended-Release vs Sublingual Buprenorphine in Pregnancy Through 12 Months Post Partum: A Randomized Clinical Trial.

JAMA internal medicine·2026
Same author

Safely Supporting the Establishment of Breastfeeding in the Setting of Fentanyl Use Before the Birth Hospitalization.

Obstetrics and gynecology·2026
Same author

Estimated Prevalence of Current Posttraumatic Stress Disorder Among Pregnant Women With Opioid Use Disorder-MATernaL and Infant Clinical NetworK (MAT-LINK), 2014-2021.

Journal of addiction medicine·2026

Related Experiment Video

Updated: Jul 19, 2025

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

283

Polysubstance Use in Pregnancy: Surveillance, Interventions, and Next Steps.

Youngjoo Park1,2, Elizabeth P Dang1, Amy Board1

  • 1National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Journal of Women'S Health (2002)
|August 8, 2023
PubMed
Summary
This summary is machine-generated.

Polysubstance use during pregnancy poses risks to maternal and infant health. The Centers for Disease Control and Prevention (CDC) identified gaps in surveillance, screening, and prevention to improve outcomes.

Keywords:
alcoholopioidspolysubstance usepregnancyprenatal substance exposuresmoking

More Related Videos

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

86.1K
A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
14:43

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

Published on: January 12, 2018

11.9K

Related Experiment Videos

Last Updated: Jul 19, 2025

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

283
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

86.1K
A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
14:43

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

Published on: January 12, 2018

11.9K

Area of Science:

  • Public Health
  • Maternal-Child Health
  • Substance Use Disorders

Background:

  • Substance use during pregnancy is linked to adverse maternal and neonatal outcomes.
  • Polysubstance use is prevalent but its risks during pregnancy are not well understood.
  • Understanding combined substance exposures is critical for effective interventions.

Purpose of the Study:

  • To review Centers for Disease Control and Prevention (CDC) activities addressing polysubstance use in pregnancy.
  • To identify gaps in surveillance, routine screening, and prevention strategies.
  • To highlight the importance of addressing polysubstance use for improved maternal and infant health.

Main Methods:

  • Overview of CDC and partner activities.
  • Identification of knowledge and programmatic gaps.
  • Literature review on polysubstance use during pregnancy.

Main Results:

  • Gaps exist in surveillance systems for tracking polysubstance use in pregnant individuals.
  • Routine screening for polysubstance use is not consistently implemented.
  • Prevention efforts require enhanced strategies to address combined substance exposures.

Conclusions:

  • Addressing identified gaps in surveillance, screening, and prevention is crucial.
  • Collaborative efforts are needed to reduce polysubstance use during pregnancy.
  • Interventions can improve health outcomes for pregnant people and their infants.